Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Long-Term Deferred Tax (2023 - 2025)

Historic Long-Term Deferred Tax for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $2.3 million.

  • Zhengye Biotechnology Holding's Long-Term Deferred Tax changed N/A to $2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is 926.75% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Long-Term Deferred Tax stood at $2.3 million.
  • Zhengye Biotechnology Holding's Long-Term Deferred Tax's 5-year high stood at $2.3 million during Q2 2025, with a 5-year trough of $1.5 million in Q4 2024.
  • Its 3-year average for Long-Term Deferred Tax is $1.8 million, with a median of $1.7 million in 2023.
  • Examining YoY changes over the last 5 years, Zhengye Biotechnology Holding's Long-Term Deferred Tax showed a top increase of 752.91% in 2024 and a maximum decrease of 752.91% in 2024.
  • Over the past 3 years, Zhengye Biotechnology Holding's Long-Term Deferred Tax (Quarter) stood at $1.7 million in 2023, then decreased by 7.53% to $1.5 million in 2024, then skyrocketed by 47.56% to $2.3 million in 2025.
  • Its Long-Term Deferred Tax was $2.3 million in Q2 2025, compared to $1.5 million in Q4 2024 and $1.7 million in Q4 2023.